CV 9202

Drug Profile

CV 9202

Alternative Names: BI 1361849; CV-9202

Latest Information Update: 29 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CureVac; Ludwig Institute for Cancer Research
  • Developer Boehringer Ingelheim; Cancer Research Institute; CureVac; Ludwig Institute for Cancer Research
  • Class Cancer vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 modulators; Toll-like receptor 8 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 24 Jan 2018 CureVac has patent protection for CV 9202 in Europe
  • 02 Jun 2017 Ludwig Institute for Cancer Research, Cancer Research Institute, Boehringer Ingelheim, MedImmune, CureVac and PharmaJet plan a phase I/II trial for Non-small cell lung cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (NCT03164772)
  • 20 Jan 2017 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy) in USA (Intradermal) (NCT03164772)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top